A new study in Science used allele-specific expression data to find candidate genes that may have contributed to mendelian muscle disease in patients.
The Irvine, California-based firm said its "Revolution" system offer recovery rates of 70 to 90 percent across a wide range of liquid sample volumes.
The firm hopes to return fewer VUS in its test reports and to accelerate the resolution of uncertain results issued to patients in that past.
The company announced this week the expansion of a genetic testing program for US patients with inherited retinal disease that it has run with partners since 2017.
The San Diego-based DNA synthesis firm this week announced $12.2 million in Series A funding, but has plans to expand the round.
The researchers hope to eventually develop a point-of-care assay to detect conditions that lead to high-risk pregnancies before symptoms occur.
According to Natera CEO Steve Chapman, the agreement will not detract from Natera's own efforts to establish its exome sequencing-based Signatera assay.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
The Royal Oaks, Michigan-based firm anticipates launching the assay — which currently analyzes 214 genes for prostate cancer risk — for research-use-only applications in H2 2020.
An initial analysis suggests the novel coronavirus from Wuhan that is sickening people might come from snakes, a team of virologists writes at the Conversation.
DNA testing confirms captured Chicago coyote same as the one that bit a boy near a nature museum, the Chicago Tribune reports.
An analysis of Tibetan ice cores uncovers more than two dozen previously unknown virus groups, LiveScience reports.
In Nature this week: genomic analysis of four children buried in Cameroon approximately 3,000 and 8,000 years ago, and more.